Boardroom Alpha
10-K primary document
GILD · Annual Report (Form 10-K) · Filed February 24, 2026

Gilead Sciences Inc10-K exhibit

gild2025formex211listingof.htm
Document

Exhibit 21.1
SUBSIDIARIES OF GILEAD SCIENCES, INC.
(as of December 31, 2025)
NAME OF SUBSIDIARYCOUNTRY OF FORMATION
Asegua Therapeutics LLCUnited States
Calla Holdings, LLCUnited States
Calla Merger Sub, Inc.United States
CymaBay Therapeutics, Inc.United States
Forty Seven, LLCUnited States
Forty Seven Holdings, LLCUnited States
Gilead Alberta, LLCUnited States
Gilead Apollo, LLCUnited States
Gilead Biopharmaceutics US LLCUnited States
Gilead Calistoga, LLCUnited States
Gilead Connecticut, Inc.United States
Gilead Holdings, LLCUnited States
Gilead Pharmasset LLCUnited States
Gilead Sciences, LLCUnited States
Gilead Sciences Holding, LLCUnited States
Immunomedics, Inc.United States
IBC Pharmaceuticals, Inc.United States
Interius Biotherapeutics, Inc.United States
Kite Pharma, Inc.United States
Kite Pharma, LLCUnited States
neoKite, Inc.United States
Tmunity Therapeutics, Inc.United States
XinThera, Inc.United States
Gilead Sciences Argentina S.R.L.Argentina
Cytopia Pty. Ltd.Australia
Gilead Sciences Pty. Ltd.Australia
Gilead Sciences YM Australia Pty. Ltd.Australia
YM BioSciences Australia Pty. Ltd.Australia
Gilead Sciences GesmbHAustria
Gilead Sciences Belgium BVBelgium
Gilead Sciences Farmacêutica do Brasil Ltda.Brazil
CymaBay Canada, Ltd.Canada
Gilead Alberta ULCCanada
Gilead Sciences Canada, Inc.Canada
Gilead YM ULCCanada
Gilead Sciences (Shanghai) Consulting Co., Ltd.China
Gilead Sciences Hangzhou Pharmaceutical Co., Ltd.China
Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd.China
Gilead Sciences Colombia S.A.S.
Colombia
Gilead Sciences s.r.o.Czech Republic
Gilead Sciences Denmark ApSDenmark
Gilead Sciences Finland OyFinland
Gilead Sciences SASFrance
Gilead Sciences GmbHGermany
Immunomedics GmbHGermany
MYR GmbHGermany
Gilead Sciences Hellas EPEGreece
Gilead Sciences Hong Kong LimitedHong Kong
Gilead Sciences India Private LimitedIndia



SUBSIDIARIES OF GILEAD SCIENCES, INC. (continued)
(as of December 31, 2025)
NAME OF SUBSIDIARYCOUNTRY OF FORMATION
CymaBay Ireland, LimitedIreland
Gilead Apollo Unlimited CompanyIreland
Gilead Biopharmaceutics Ireland UCIreland
Gilead Sciences Ireland Unlimited Company    Ireland
Gilead Therapeutics A1 Unlimited CompanyIreland
Gilead Sciences Israel LimitedIsrael
Gilead Sciences S.r.l.Italy
Gilead Sciences KKJapan
Gilead Sciences Luxembourg S.a.r.l.Luxembourg
Gilead Sciences Malaysia Sdn. Bhd.Malaysia
Gilead Sciences Mexico S. de R.L. de C.V.Mexico
Gilead Sciences Netherlands B.V.Netherlands
Kite Pharma EU B.V.Netherlands
KP EU C.V.Netherlands
Gilead Sciences (NZ)New Zealand
Gilead Sciences Norway ASNorway
Gilead Sciences Americas S. de R.L.Panama
Gilead Sciences Poland Sp. z.o.o.Poland
Gilead Sciences, Lda.Portugal
Gilead Sciences (GSR) S.R.L.Romania
Gilead Sciences Russia LLCRussia
Gilead Sciences Arabia Limited CompanySaudi Arabia
Gilead Sciences Singapore Pte. Ltd.Singapore
Gilead Sciences Slovakia s.r.o.Slovakia
Gilead Sciences South Africa (Pty) Ltd.South Africa
Gilead Sciences Korea LimitedSouth Korea
Gilead Sciences S.L.U.Spain
Gilead Sciences Sweden ABSweden
Gilead Sciences Switzerland SarlSwitzerland
Gilead Sciences Ilac Ticaret Limited Sirketi
Turkey
CymaBay UK, Ltd.United Kingdom
Gilead Sciences Europe LimitedUnited Kingdom
Gilead Sciences International LimitedUnited Kingdom
Gilead Sciences LimitedUnited Kingdom
MiroBio Ltd.United Kingdom


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer